Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China

    NEXT STORY
    Syneos Health Acquires Illingworth Research Group, a Leading Provider of Clinical Research Home Health Services
    PREV STORY
    BioSig’s Division NeuroClear Technologies Signs a Research Agreement with the University of Minnesota
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aptose Biosciences and CrystalGenomics Announce Issuance of Japanese Patent for CG-806

    SAN DIEGO, TORONTO, and SEOUL, July 10, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ...

    author_avatar
    NASDAQ Market News

    POC Diagnostics Industry 2019-2024, 7th Edition – A Deep Look Into the Shift from Curative Medicine to Predictive, Personalized, and Preemptive Medicine

    author_avatar
    NASDAQ Market News

    VBL Therapeutics Announces First Quarter 2018 Financial Results

    Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, May 17, ...

    author_avatar
    NASDAQ Market News